Colonic epithelial response to injury requires Myd88 signaling in myeloid cells

Nicole P. Malvin#, Hiroshi Seno#, and Thaddeus S. Stappenbeck#
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA

# These authors contributed equally to this work.

Abstract

Proper colonic injury response requires myeloid-derived cells and Toll-like receptor/Myd88 signaling. However, the precise role of Myd88 signaling specifically in myeloid-derived cells that occurs during tissue damage is unclear. Therefore, we created a mouse line with Myd88 expression restricted to myeloid lineages (Myd88−/−; LysMCre+/+; ROSA26Myd88+/+; herein Mlcr). In these mice, Myd88 was appropriately expressed and mediated responses to bacterial ligand exposure in targeted cells. Importantly, the severe colonic epithelial phenotype observed in dextran sodium sulfate-injured Myd88−/− mice was rescued by the genetic modification of Mlcr mice. During injury, myeloid cell activation and enrichment of Ptsg2-expressing stromal cells occurred within the mesenchyme that surrounded the crypt bases of Mlcr and Myd88+/− mice but not Myd88−/− mice. Interestingly, these cellular changes to the crypt base mesenchyme also occurred, but to a lesser extent in uninjured Mlcr mice. These results show that Myd88 expression in myeloid cells was sufficient to rescue intestinal injury responses and surprisingly, these cells appear to require an additional Myd88-dependent signal from a non-myeloid cell type during homeostasis.

Introduction

The mouse colon is a distinctive model system that can be utilized to elucidate functional cellular components that mediate damage responses. The epithelium is an absorptive barrier composed of a single layer of cells lining the inner surface of the colonic tube. The apical side of this barrier contacts a substantial and diverse set of indigenous microbes while the basal side contacts cells of the immune system and the stroma.1-3 Studies of colonic wound responses and repair suggest this process requires interaction with both the apically located microbes and the baso-laterally located cells of the innate immune system and stroma.4

The mouse colonic epithelium is designed to quickly respond to injury. Cellular turnover is already quite elevated during homeostasis (~3-5 days). New epithelial cells are supplied from ~100,000 crypts that are organized in a high density array (~400 crypts/mm²). Stem and proliferative progenitors are located at the base of each crypt.5 6 Their daughters exit the cell cycle and migrate upwards and eventually out of crypts onto the inner surface of the intestine. To properly respond to injury, stem and progenitor cells alter their activity to repopulate damaged crypts and the epithelial barrier.7
Interaction of the epithelium with mesenchymal cells is critical for proper injury response. In the colon, a number of cell types have been proposed to play a role in injury repair using a variety of experimental systems. Myeloid cells are often a prominent cell type within areas of intestinal damage and engage in an important function of killing and clearing microbes. Under certain circumstances, these cells appear to play a role in the proper response to injury. For example, in the intestine, mice with greatly diminished peripheral myeloid cells (Csf1op/op mice) when injured with the toxin dextran sodium sulfate (DSS) show loss of proliferation in colonic epithelial progenitors supporting a positive role for myeloid cells in the response to tissue injury. Elimination of myeloid cells using the inducible diphtheria toxin receptor model showed that these cells play a role in specific phases of skin wound healing.

Toll-like receptor signaling through the Myd88 adaptor protein is a critical signaling pathway required for proper colonic injury response to DSS. This signaling is responsible for microbial recognition, induction of antimicrobial products and modulation of the adaptive immune response. TLRs are key recognition molecules within the colon, functioning within many specialized cells, potentially including epithelial cells, myofibroblasts and professional immune cells.

We previously Myd88 signaling was upstream of focal prostaglandin E2 (PGE2) production during DSS injury. A rate limiting enzyme for the production of PGE2 is Ptsg2 (also known as Cox-2). We and others have found that this gene is highly expressed in a population on non-hematopoietic cells in the stroma of the mouse colon and that in vitro these cells are consistent with mesenchymal stem cells. In non-ulcerated areas of DSS damage in the mouse rectum, we found that the positioning of the Ptgs2 expressing stromal cells was important to maintain colonic epithelial proliferation during this injury. We proposed that the position of these cells was important because PGE2 has a very short half-life and its delivery closer to intestinal epithelial progenitors that are its target would increase its effects. PGE2 has been proposed to stimulate Wnt signaling which is required for intestinal epithelial progenitor function during injury.

Our model is that to maintain colonic epithelial proliferation during DSS injury, Myd88 signaling is required in a lineage distinct from the Ptgs2 expressing stromal cells. One reason is that the latter cell type does not respond to TLR ligands such as LPS as they lack CD14 expression. Based on our findings with Csf1op/op mice, we developed the hypothesis that Myd88 signaling was required in myeloid cells for the proper response to DSS damage. To test this hypothesis, we created a novel mouse line with Myd88 expression that was restricted to these cells. Here, we show that our targeting strategy produced appropriate expression of Myd88 in myeloid cells and that this expression was sufficient to rescue the phenotype observed in DSS-injured Myd88−/− mice.

Results

Generation and validation of the Mlcr mouse strain

We engineered a mouse line that contained Myd88 expression in myeloid derived cells. We ‘knocked in’ the Myd88 cDNA into the Rosa26 locus immediately downstream of its floxed stop signal (Figure 1a-c). ROSA26ΔMyd88+ mice were bred to Myd88−/− and their progeny were then bred to LysMCre/Cre mice. We used this Cre line as recombination has been widely reported to occur in myeloid lineages including macrophages, GR-1+ leukocytes and dendritic cells. The breeding scheme generated Mlcr mice (Myd88−/−;LysMCre/+;ROSA26ΔMyd88+) as well as two littermate control groups: Myd88+/−;LysMCre/+;ROSA26Δ/+ (herein Myd88+/−) and Myd88−/−;LysMCre/+;ROSA26Δ/+. We generated Myd88+/− mice as controls with this genotype.
have been shown to be functionally equivalent to \textit{Myd88}^{+/+} mice.\textsuperscript{29} Using breeding scheme one (generated \textit{Mlc}r, \textit{Myd88}^{−/−} and \textit{Myd88}^{+/−} mice), we found that the distribution of mice obtained was not significantly different than the expected Mendelian ratio (Table 1). Using breeding scheme two (generated \textit{Mlc}r and \textit{Myd88}^{−/+} mice), we found that \textit{Mlc}r mice were present at ratios significantly higher than the expected Mendelian frequencies (Table 1).

To validate the genetic targeting, we determined the level of \textit{Myd88} expression in myeloid cells and fibroblasts isolated from colons of \textit{Mlc}r and control mice (\textit{Myd88}^{−/−} and \textit{Myd88}^{+/−}). We isolated an enriched population of colonic myeloid cells (>95\% F4/80 positive) using a protocol based on multiple previous studies.\textsuperscript{30-33} (Supplemental Figure 1a, b). Using quantitative (q)RT-PCR analysis, \textit{Myd88} expression was at the limit of detection in myeloid cells isolated from \textit{Myd88}^{−/−} mice and was detectable at comparable levels in cells isolated from \textit{Mlc}r and \textit{Myd88}^{+/−} mice (Figure 2a). To confirm the specificity of \textit{LysM-Cre} in the \textit{Mlc}r mice, we evaluated \textit{Myd88} mRNA expression in colonic fibroblasts isolated as previously described.\textsuperscript{21} \textit{Myd88} expression was at the limit of detection in fibroblasts isolated from \textit{Mlc}r and \textit{Myd88}^{−/−} mice and was detectable in cells isolated from \textit{Myd88}^{+/−} mice (Figure 2b). We confirmed in separate experiments that \textit{Myd88}^{+/+} and \textit{Myd88}^{+/−} mice from our colony expressed similar levels of \textit{Myd88} mRNA (Supplemental Figure 1c, d). We also performed immunofluorescence localization of \textit{Myd88} on colonic sections using tyramide amplification. By this method, we detected \textit{Myd88} in the crypt epithelium of \textit{Myd88}^{+/+} and \textit{Myd88}^{+/−} mice but not in the epithelium of \textit{Mlc}r and \textit{Myd88}^{−/−} mice (Supplemental Figure 1e-h). Thus, constitutive expression of \textit{Myd88} mRNA occurred as expected based on the known cellular targets of \textit{LysM-Cre}.

\textbf{Myeloid cells in \textit{Mlc}r mice have functional expression of \textit{Myd88}}

To perform functional tests of \textit{Myd88} expression in \textit{Mlc}r mice, we isolated bone marrow monocytes and performed \textit{in vitro} differentiation for macrophages (M-CSF) and dendritic cells (GM-CSF)\textsuperscript{34} and confirmed appropriate expression of \textit{Myd88}. We chose this model as both of these cell populations are readily expanded \textit{in vitro}. As expected, \textit{Myd88} expression in macrophages and dendritic cells derived from \textit{Myd88}^{−/−} mice was at the limits of detection. \textit{Myd88}^{+/−} and \textit{Mlc}r mice expressed comparable levels of \textit{Myd88} mRNA in bone marrow derived macrophages (Figure 3a). As an additional control, we found the levels of \textit{Myd88} expression were similar in \textit{Myd88}^{+/−} and \textit{Myd88}^{+/+} bone marrow derived macrophages (Supplement Figure 1i). The levels of \textit{Myd88} expression in dendritic cells from \textit{Mlc}r mice were 1.6-fold less than those isolated from \textit{Myd88}^{+/−} mice.

As \textit{Myd88} expression is critical to drive responses to bacterial products,\textsuperscript{14-16} we treated bone marrow derived macrophages and dendritic cells from \textit{Mlc}r and control mice with LPS and evaluated gene expression of two well-known targets, \textit{Ptgs2} and \textit{TNFα}\textsuperscript{15, 21}. At baseline, gene expression for both \textit{Ptgs2} and \textit{TNFα} showed no significant differences based on genotype for both macrophages and dendritic cells (Figure 3b, c; Supplemental Figure 1j, k). LPS-treated macrophages and dendritic cells from \textit{Myd88}^{+/−} and \textit{Mlc}r mice expressed higher levels of \textit{Ptgs2} and \textit{TNFα} as compared to corresponding LPS-treated \textit{Myd88}^{−/−} cells (Figure 3d, e; Supplemental Figure 1j, k). Taken together, these results were consistent with functional levels of \textit{Myd88} expression in myeloid cells isolated from \textit{Mlc}r mice.

\textbf{Myeloid expression of \textit{Myd88} rescues the DSS injury phenotype of \textit{Myd88}^{−/−} mice}

We next evaluated the colonic damage response of adult mice treated for one week with 2.5\% DSS. This experimental treatment created multiple focal ulcers in the transverse colon as well as a single confluent ulcer at the ano-rectal junction in \textit{Mlc}r mice as well as their littermate controls. Importantly, the descending colons of DSS-treated \textit{Mlc}r mice and controls were neither ulcerated nor inflamed as evidenced by the absence of accumulated

\textit{Mucosal Immunol.} Author manuscript; available in PMC 2013 October 07.
mucosal neutrophils in this location for any group of DSS-treated mice (Supplemental Figure 2a). These findings were similar to previous studies with DSS treated mice.\textsuperscript{10, 13}

We next performed histological analysis of descending colons from groups of untreated and DSS-treated mice. The descending colon of untreated Mlc\textsubscript{r} mice was similar in appearance to untreated colons from \textit{Myd88}\textsuperscript{+/−} and \textit{Myd88}\textsuperscript{−/−} mice (Figure 4a-c). We found no discernible differences when comparing untreated and DSS-treated \textit{Myd88}\textsuperscript{+/−} mice (Figure 4a, d). In contrast, DSS-treated \textit{Myd88}\textsuperscript{−/−} mice contained extensive crypt atrophy, loss of crypt epithelial cells, and a thickened muscularis propria as compared to untreated \textit{Myd88}\textsuperscript{−/−} mice (Figure 4b, e). Interestingly, the descending colons from DSS-treated Mlc\textsubscript{r} mice showed no apparent differences in comparison to untreated Mlc\textsubscript{r} mice (Figure 4c, f). These results showed that expression of Myd88 in myeloid cells rescued the effects of DSS injury in \textit{Myd88}\textsuperscript{−/−} mice. LysM targets multiple myeloid cell types including macrophages, dendritic cells and neutrophils.\textsuperscript{27, 28} We found that ablation of neutrophils in WT mice did not alter the epithelial response to DSS treatment, suggesting this cell type is not required (Supplementary Figure 2b-d).

As the descending colonic crypts were a primary morphologic target of DSS in \textit{Myd88}\textsuperscript{−/−} mice, we qualitatively evaluated crypt size by H+E staining and epithelial proliferation by BrdU incorporation to visualize cells in S-phase (Figure 5a-f). These stained sections showed that crypts from DSS-treated \textit{Myd88}\textsuperscript{−/−} mice contained fewer total and S-phase cells as compared to all other groups of mice. We next performed quantitative analysis of epithelial proliferation, cell census and cell death of the intestinal epithelium in DSS-treated and untreated mice (Figure 5g-j). Quantification of total numbers of epithelial cells/crypt, M-phase cells/crypt and S-phase cells/crypt showed that DSS-treated \textit{Myd88}\textsuperscript{−/−} mice had a significant reduction in cell census and proliferation as compared to untreated \textit{Myd88}\textsuperscript{−/−} mice (Figure 5g-i). These differences were present for all the genetic subgroups of \textit{Myd88}\textsuperscript{−/−} mice obtained by our breeding scheme (Supplementary Figure 2e-g). Importantly, we found that DSS-treated Mlc\textsubscript{r} mice showed no reduction in epithelial cell census and proliferation compared to untreated Mlc\textsubscript{r} mice (Figure 5g-i). The findings for DSS-treated Mlc\textsubscript{r} mice were comparable to similarly treated \textit{Myd88}\textsuperscript{+/−} controls (including subgroups of \textit{Myd88}\textsuperscript{+/−}, Supplementary Figure 2e-g). Quantification of apoptosis was determined by visualization of apoptotic bodies in the epithelium.\textsuperscript{10, 13} This analysis showed no significant differences when comparing DSS-treated and untreated mice for all three genotypes (Figure 5j).

\textbf{Mlc\textsubscript{r} mice contain activated colonic myeloid cells during DSS injury}

We previously found that based on morphology, activated myeloid cells were present in the peri-crypt base mesenchyme of DSS-treated wild-type but not similarly treated \textit{Myd88}\textsuperscript{−/−} mice.\textsuperscript{10} To test if Myd88 expression within myeloid cells stimulated activation during injury, we analyzed slides co-labeled with antisera directed against F4/80 and CD86. The latter is a recently established marker of macrophage activation.\textsuperscript{35-38} In mice of all three genotypes, CD86 positive aggregates were preferentially located in the crypt base associated mesenchyme and often co-localized with F4/80 (Figure 6a, b). Quantification of the number of double positive aggregates (CD86 and F4/80) per crypt associated mesenchyme showed significantly higher numbers in DSS-treated \textit{Myd88}\textsuperscript{+/−} and Mlc\textsubscript{r} mice as compared to untreated genotype controls (Figure 6c). As an additional control, the numbers of double positive aggregates were similar in DSS-treated and untreated \textit{Myd88}\textsuperscript{+/−} and \textit{Myd88}\textsuperscript{+/+} (Supplementary Figure 8). In contrast, the number of double positive aggregates was not significantly increased in DSS-treated versus untreated \textit{Myd88}\textsuperscript{−/−} mice (Figure 6c). As an additional control, we found that nearly all of the CD86 positive aggregates co-localized with F4/80 in DSS-treated \textit{Myd88}\textsuperscript{+/−}, \textit{Myd88}\textsuperscript{+/+} and Mlc\textsubscript{r} mice (Figure 6d; Supplemental
Figure 2h, i). These data support a major role for Myd88 signaling in myeloid cell activation during DSS injury.

**Mlcr mice contain Ptgs2 expressing stromal cells that are preferentially distributed near the crypt base**

We previously found that in response to DSS treatment, PGE2 produced by the rate limiting enzyme Ptgs2 acts downstream of Myd88 in order to maintain colonic epithelial proliferation.\(^{21}\) We also previously established that Ptgs2 expression is readily detectable in mesenchymal stem cells (a.k.a. fibroblasts) both *in vivo* and *in vitro*.\(^{21}\) Interestingly, it is the distribution of Ptgs2-expressing stromal cells that is dependent on Myd88 signaling and is associated with maintenance of colonic epithelial proliferation during DSS treatment.\(^{13}\)

Therefore, we determined the localization of Ptgs2 in tissue sections from DSS treated and untreated mice from all three genotypes. In all groups, we observed scattered Ptgs2-expressing stromal cells (PSCs) that were negative for F4/80 and CD11c antigens (Figure 7a-f). These cells were consistent with fibroblasts by additional marker studies.\(^{13}\) Quantification of PSCs showed no significant differences in abundance of these cells when comparing groups based on genotype or treatment (Figure 7g), similar to previous studies.\(^{13}\) We then determined the levels of Ptgs2 mRNA expression in colonic fibroblasts and colonic myeloid cells isolated from *Mlcr, Myd88\(^{+/−}\)* and *Myd88\(^{−/−}\)* mice. For all three genotypes, we found that the expression of Ptgs2 in fibroblasts was significantly higher than myeloid cells (Figure 7h). Additional experiments showed *Myd88\(^{+/+}\)* also expressed higher levels of Ptgs2 in fibroblasts as compared to myeloid cells (Supplementary Figure 3a). These findings are consistent with previous studies that show PSCs (fibroblasts) are a prominent source of Ptgs2 in the descending colon in both untreated and DSS treated mice of multiple genotypes.\(^{13, 20}\)

We previously found that the localization of PSCs was altered in response to DSS treatment in a Myd88-dependent fashion.\(^{13}\) As anticipated, PSCs were enriched in the peri-crypt base region of DSS-treated *Myd88\(^{+/−}\)* mice (versus untreated controls) but were not enriched in this region of DSS-treated *Myd88\(^{−/−}\)* mice (versus untreated controls; Figure 8a, b). As an additional control we compared the distribution of PSCs in untreated and treated *Myd88\(^{+/−}\)* versus untreated and treated *Myd88\(^{+/+}\)* (that we previously reported)\(^{13}\) and found no differences. Importantly, DSS-treated *Mlcr* mice contained a similar enrichment of PSCs in the peri-crypt base region (versus untreated *Mlcr* mice). Thus, expression of Myd88 in myeloid cells was sufficient to alter the distribution of PSCs during DSS injury.

**Myeloid cells in untreated Mlcr mice are in a mildly activated state**

An unexpected finding was an enrichment of PSCs in the peri-crypt base region of untreated *Mlcr* mice as compared to untreated *Myd88\(^{+/−}\)* and *Myd88\(^{−/−}\)* mice (Figure 8b). As the DSS experiments showed that myeloid cell activation was correlated with altered PSC distribution, we re-analyzed the data from Fig. 6c considering only the untreated groups of mice and found a significantly greater number of double-positive (CD86/F4/80) aggregates in untreated *Mlcr* mice as compared to both untreated control groups (ANOVA with a Tukey’s post-test, P<0.01). This finding indicated a mild level of colonic myeloid cell activation in untreated *Mlcr* mice. We then evaluated mRNA expression of additional markers of myeloid cell activation and found small but significant increases in isolated colonic myeloid cells from untreated *Mlcr* mice as compared to control groups (Figure 9; Supplementary Figure 3b). This difference was not correlated with an alteration in the expression of anti-inflammatory cytokines in *Mlcr* mice (Supplementary Figure 3c, d). Thus, the myeloid cells in *Mlcr* colons appear to be mildly activated.
As enhanced activation of NFκB in the intestinal epithelium leads to inflammation, fibrosis and tumorigenesis in aged mice, we evaluated the gross and histologic pathology of 12-13 month old Mlcr mice. Interestingly, there was no evidence of inflammation, fibrosis or tumorigenesis. In contrast, there was a decrease in epithelial proliferation in the transverse colon as compared to littermate controls (Supplementary Figure 3e, f).

Discussion

In this study, we determined the role of Myd88 signaling in myeloid derived cells. We first created a mouse model (Mlcr) where Myd88 expression was directed to this lineage using a myeloid specific Cre and a Myd88 cDNA knocked into the ROSA26 locus. We found this genetic system appropriately restricted Myd88 expression to cell types known to be targeted by LysM-Cre and mediated effects in isolated myeloid-derived cells. Importantly, we showed that restricted expression of Myd88 using LysM-Cre was sufficient to rescue the phenotype in Myd88−/− DSS-injured mice. The colonic features of this mouse model during DSS treatment were comparable to similarly treated Myd88+/- mice and included epithelial responses to damage, myeloid cell activation and localization of Ptgs2-expressing stromal cells. Interestingly, we found that in uninjured mice, the Mlcr line contained mildly activated colonic myeloid cells, indicating that Myd88-signaling in non-myeloid lineages can inhibit myeloid activation.

Myd88 plays a role in numerous biologic processes within a variety of tissues that include wound repair in lung and skin, cancer and host defense against pathogens. Creation of a floxed allele of this gene by other investigators has been beneficial to determine if deficiency in a particular lineage(s) is required for the function of Myd88 in the whole animal. In contrast to a transgenic over-expression approach, we designed our model with the intention to create a flexible genetic system based on breeding to additional Cre lines. In addition, we found that Mlcr mice contained levels of Myd88 expression in myeloid cells that was comparable to myeloid cells isolated from Myd88+/- and Myd88+/- mice. In contrast to bone marrow chimeras where radio-resistant tissue myeloid cells could possibly confound interpretation, our system has the advantage of more precise control of Myd88 expression. We anticipate that our model should complement findings using a floxed Myd88 allele.

We chose LysM-Cre to test the role of Myd88 in myeloid cells as this Cre targets macrophages and dendritic cells and thus mimics the cell types in the colon that are diminished in mice with Csf1 inactivating mutations. Thus, we could evaluate the role of Myd88 expression in comparable cell types. LysM-Cre also targets neutrophils. Here and in our previous study, we have found no obvious role for neutrophils in the response to DSS injury. In addition, we examined an area of the colon that does not undergo extensive damage during DSS treatment and thus there is no accumulation of neutrophils in this area. For these reasons, we focused our analysis on monoctye-derived cells in Mlcr mice.

We previously found a robust, Myd88-dependent, simultaneous elevation of mRNA signatures for both classical and alternative forms of macrophage activation in the mesenchyme of DSS-treated mice. We evaluated the expression of CD86 as it is well-recognized as a marker of activated macrophages under both conditions of classical and alternative activation. Elevated CD86 expression in myeloid cells has been reported in a model of spontaneous colitis (Stat3f/f;LysMCre+). CD86 can be expressed in antigen presenting cells where it has costimulatory properties. Here, using CD86 as a readout, we found that Myd88 expression in myeloid cells was sufficient to drive myeloid cell activation during DSS treatment.
An unexpected finding was that colonic myeloid cells in untreated Mlcr mice showed evidence of mild activation as compared to untreated Myd88−/− mice. This finding suggests that a source of Myd88 stimulation was unmasked and could include either microbial or host derived factors. The finding also suggests the possibility that an additional cellular source of the Myd88 expression may reduce myeloid activation in a non-cell-autonomous manner. This question is of importance as myeloid derived cells in the intestine are hypoactive in the gut. Thus, the Mlcr model should be an interesting system to approach this question and determine the interactive roles of Myd88 signaling in multiple lineages of the intestine.

Materials and Methods

Mice

The Washington University Medical School Animal Studies Committee approved all animal experiments. Mice were maintained in a specific pathogen–free barrier facility under a strict 12-hour light/dark cycle and fed autoclaved chow diet (B&K Universal Ltd.). 6–10 week old mice were used for experiments. We treated with DSS as previously described.

Generation of Mlcr mice

We subcloned the cDNA for Myd88 into Rosa26PA. The linearized targeting vector was electroporated into F1 B6/129SV ES cells. Positive clones were identified by Southern blotting, injected into C57/B6 blastocysts and implanted into surrogates. Mice with germline transmission were bred to Myd88−/− and LysMCreCre mice (Jackson laboratories). All experimental mice were littermates on a mixed C57B6/129SV background.

Genotyping

Myd88 locus—Primers: Myd88 Forward 5′ TGG CAT GCC TCC ATC ATA GTT AAC C 3′ Myd88 Reverse 5′ AGA AAC AAC CAC CAT GC 3′ Myd88 Neo 5′ GCC TTC TAT CGC CTT CTT GAC G 3′

PCR protocol: 5°C for 2min; followed by 30 cycles of: 95°C for 30sec, 60°C for 30sec, and 72°C for 30sec; followed by 72°C for 5 min. PCR products were visualized on 2.75% TBE agarose gels run for 1.5 hrs at 100 volts to clearly separate the amplicons. A 550 base pair amplicon indicated a wild-type Myd88 locus and a 600 base pair amplicon indicated a knockout Myd88 locus.

Mlcr locus—Primers: Forward 5′ CCC CAA CGA TAT CGA GTT TG 3′ Reverse 5′ TTC GCA AGG GTT AT 3′

PCR 95°C for 2min; followed by 35 cycles of: 95°C for 20sec, 55°C for 30sec, and 72°C for 70sec; followed by 72°C for 5 min. Refer to Table 2 for interpretation of the 3 potential amplicons.

LysM-Cre locus—Primers: Forward 5′ AGG TTC GTT CAC TCA TGG A 3′ Reverse 5′ TCG ACC AGT TTA GTT ACC C 3′

PCR 95°C for 2min; followed by 30 cycles of: 95°C for 30sec, 60°C for 30sec, and 72°C for 30sec; followed by 72°C for 5 min. A 220 base pair amplicon indicated presence of Cre in the LysM locus.

Histochemistry and immunohistochemistry

Colons were dissected, submerged in Bouin’s fixative for 4 hrs at 24°C or methacarn fixative for 2 hrs at 24°C, and embedded in 2% agar for paraffin processing. Serial 5-
thick sections of the descending colons were cut along the cephalocaudal axis and perpendicular to the mucosal surface. Sections were stained with H&E. For frozen sections, dissected colons were flushed first with PBS followed by OCT media, arranged as 2 cm segments in histology cassettes and frozen with Cytocool. Serial 7-μm-thick sections of descending colons were cut along the cephalocaudal axis and perpendicular to the mucosal surface.

We performed intraperitoneal injections in mice with a solution containing BrdU (120 mg/kg) and 5-Fluoro-2-deoxyuridine (12 mg/ml; Sigma-Aldrich) 1 hr prior to sacrifice. S-phase cells were identified in tissue sections using goat anti-BrdU IgG.

Ptgs2 localization was performed on 5-μm-thick sections of methacarn fixed tissues stained with mouse IgG1 anti-Ptgs2 mAb (clone 33; BD Biosciences; 1:50) and the Zenon antibody labeling system (Invitrogen) as previously described. For co-labeling experiments with Ptgs2, F4/80 and CD11c 7-μm-thick sections of frozen tissue were stained with mouse IgG1 anti-Ptgs2 mAb (clone 33; BD Biosciences; 1:50) and the Zenon antibody labeling system (Invitrogen), rat IgG2b anti-mouse F4/80 mAb directly conjugated to Alexa-488 (clone CI:A3-1; Biolegend; 1:100) and Armenian hamster IgG anti-mouse CD11C mAb directly conjugated to Alexa-647 (clone N418; Biolegend; 1:50 O/N 4°C). Ig isotype controls for all antibodies used for all immunofluorescence studies. Myd88 was detected on frozen, methanol fixed sections using an overnight incubation of rabbit anti mouse Myd88 antisera (Abcam, 1:750 dilution) followed by tyramide amplification of signal (Invitrogen).

Co-localization of the macrophage activation marker CD86 and F4/80 was performed on 7-μm-thick sections of frozen tissue stained with rat IgG2a anti-mouse CD86 mAb directly conjugated to PerCP (clone GL:1; Biolegend; 1:100) and rat IgG2b anti-mouse F4/80 mAb directly conjugated to Alexa-488 (clone CI:A3-1; Biolegend; 1:100). These stained tissue sections were used to analyze CD86 aggregate per crypt base mesenchyme that co-localized with F4/80 positive cells.

Cell Culture media

Bone marrow derived macrophage conditioned media (BM20) consisted of DMEM media supplemented with 10% FBS, 20% L-cell supernatant (from L929 fibroblasts) 5% horse serum, 1% L-glutamine, 1% sodium pyruvate, 1:100 of 1M Hepes, 1 μl/ml of 10,000 U/ml Penicillin/Streptomycin (Abx), with media changed on day 4 and 7. Bone marrow derived dendritic cells culture media (DC10) was RPMI1640 media supplemented with 10%FBS, 1 μl/ml of 10,000U/ml Penicillin/Streptomycin, 2% L-glutamine, 2% GM-CSF supernatant (B78hi hybridoma) 1% sodium pyruvate, 1% non-essential amino acids, media changed on day 4, 6, and 7.

Fibroblast media consisted of DMEM media supplemented with 10mM Hepes, 10% FBS, and 1 μl/ml of 10,000U/ml Penicillin/ Streptomycin. Isolation from colon removed from one mouse, rinsed with 1:1 DMEM:HBSS miniced in DMEM:10mM Hepes treated with 100 μl of collagenase type 1 (from Clostridium histolyticum, by Invitrogen) and 20 μl of 1M DTT after tissue disruption.

Colonic myeloid cell isolation media consisted of DMEM media supplemented with 10mM Hepes, 1 μl/ml of 10,000 U/ml penicillin/streptomycin, L-glutamate in both DM10 and DM-Abx and 10% FBS in DM10 only.

Mucosal Immunol. Author manuscript; available in PMC 2013 October 07.
Isolation of fibroblasts and myeloid cells from the colon and macrophages and dendritic cells derived from bone marrow

Colonic stromal fibroblasts were isolated from individual mice as previously described. Cells were cultured in supplemented DMEM until confluent, media changed every 3 days.

Bone marrow derived macrophages and dendritic cells were cultured from bone marrow flushed from the femurs and tibias of a single mouse into 30 mls of DMEM. The cell suspension was split into two equal portions and 35 mls of a specific conditioned media was added to each aliquot. The cell suspensions were then pipetted into 10X15 cm non-tissue culture petri dishes (5 plates, 10 mls/plate) and the cells were incubated in a standard tissue culture incubator for 7 days to stimulate differentiation into either macrophages (incubated in BM20 media) or dendritic cells (incubated in DC10 media). For LPS experiments, cells were treated with EDTA to remove them from the plate. The cells were then re-plated at 1.25 x 10^5 cells per ml for 18h overnight and then treated for 1 hr with 10ng/ml LPS from E. coli (Sigma Aldrich, St. Louis, Mo) or fresh conditioned media.

Mouse colonic myeloid cells were isolated using a protocol derived from multiple previous studies. Briefly, whole colons were removed, flushed with 1:1 DMEM:PBS, cut into 1mm pieces using a sterile razor blade and the fragments were then placed in a sterile beaker with 40 mls of DM10, 400 μl of 0.5M EDTA, and 37.7 μl of 1M DTT. The suspension was placed in an orbital shaker (250 RPM) for 20 minutes at 37°C and then filtered using a 100 μm cell filter (Fisher). The tissue fragments were washed three times with shaking in DM-Abx supplemented with 400 μl of 0.5M EDTA and filtered after each wash. The washed tissue fragments were further minced with sterile razor blade and the fragments were placed in 15mls of DM-Abx supplemented with 475 μl of 5mg/ml collagenase IV and 150 μl of 10mg/ml Dnase. The suspension was placed in an orbital shaker (250 RPM) for 30 minutes at 37°C. The suspension was then passed through a 70 μm cell filter. The media was then 15mls of DM10 supplemented with 150 μl of DNAse (10mg/ml) was added. The suspension was centrifuged at 1200g for 5 minutes at 24°C. The media was carefully removed and the cell pellet was re-suspended in 12mls of DM10. The cells were then plated in a non-tissue culture treated petri dish for 1 hr. The adherent cells were washed three times with sterile PBS. The cells were then treated with 5mls of EDTA/PBS and incubated at 4°C for 10 minutes. The plate was scraped to remove adherent cells. The cells were re-suspended in 5mls of DM10 and 5mls of EDTA/PBS and centrifuged at 1200g for 5 minutes to pellet the myeloid cells.

RNA extraction and qRT-PCR analysis

RNA was extracted using NucleoSpin® RNA II (Clontech Laboratories) for colonic fibroblasts and bone marrow derived macrophages and dendritic cells. Colonic myeloid cell RNA was isolated using the PicoPure® RNA Isolation Kit (Applied Biosystems). The quality and quantity of all RNAs was evaluated by Nanodrop (Thermo Scientific). Random primed cDNA (Superscript III, Invitrogen) was used as a template for qRT-PCR that was performed in triplicate for each biologic sample using SYBR Advantage (Clonetech). The threshold cycle (C_T) of the gene of interest was subtracted from the baseline C_T (18s mRNA) to calculate a change in C_T (ΔC_T). To calculate the fold change in gene expression the ΔC_T for each measurement was subtracted from the baseline ΔC_T (average ΔC_T of Myd88 +/- untreated cells mRNA).

Primers used for qPCR

18S (5′-CATTCGAACGTCTGCCCTATC, 5′-CCTGTGCTCTTCTTCCTTGGA), Ptgs2 (5′-TGCTTGTCCTGATGATGTAG, 5′-GGGGTGCCAGTGATAGTGTG), TNF-Δ (5′-GGGTGCCAGTGATAGTGTG), Myd88 (5′-CCCTCACTCAGATCTCTTCT, 5′-CTACGACGGGTGGCTACAG), and Myd88 (5′-
CACCTGTGTCTGGTCCATTG, 5′-CTGTGGACACCTGGAGACA). The latter primers were designed to include exons 4 and 5 so as to amplify only intact mRNA as found in Myd88+/− but not Myd88−/− mice.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank E. Unanue W. Stenson, N. Manieri and M. Walker for comments on the manuscript and M. White for microinjection of targeted ES cells. Funding by the National Institutes of Health (DK071619), Crohn’s Colitis Foundation of America, Pew Scholars Foundation and Washington University Digestive Disease Research Core (NIH P30-DK52574)

References


**Figure 1. Generation of Micer mice**

(a) Targeting of Myd88 cDNA into the ROSA26 locus. The targeting construct included two homology arms indicated as SA (the ‘short arm’ at the 5′ position of the targeting construct) and LA (the ‘long arm’ at the 3′ position), the Myd88 cDNA, as well as two flox sites (denoted by filled triangles) that flank the neomycin resistance gene plus its three tandem polyadenylation sites (3pA). The map indicates proper targeting of the construct into the ROSA26 locus by homologous recombination as well as the predicted effects of Cre mediated excision on a properly targeted locus. EcoRV digestion of genomic DNA was used to map clones and anticipated sizes of DNA fragments were indicated. (b, c) Southern blots showed clones that are either not targeted (WT) or properly targeted (KI) using (b) 5′ and (c) 3′ probes. The targeted ROSA26 locus contained a 4.0 kb EcoRV DNA fragment recognized by Probe1 and a 9.2 kb EcoRV DNA fragment recognized by Probe2.
Figure 2. Micer mice expressed Myd88 mRNA in colonic isolated myeloid cells

Graphs of the percent fold-difference of Myd88 mRNA expression of isolated colonic cell populations. (a) Isolated colonic myeloid cells. (b) Isolated colonic fibroblasts. For each cell type, Y-axis values were calculated as percentage of a fold difference of Myd88 mRNA expression by qRT-PCR analysis. The fold difference was calculated as the difference between the average \( \Delta C_T \) of the experimental cell type and average \( \Delta C_T \) of the control cells (untreated Myd88\(^{+/−}\)) divided by the control \( \Delta C_T \). Mean values ± SEM were plotted for each group (N=4-6 samples/group performed in 2 separate experiments). Triple asterisks indicate a statistically significant difference between two groups (P<0.001) as determined by a one way ANOVA with a Tukey’s post-test.
Figure 3. Bone marrow derived macrophages and dendritic cells from Mler mice showed elevated Ptgs2 and TNF α production in response to LPS treatment

(a) Graphs of the percent fold-difference of Myd88 mRNA expression in bone marrow (BM) derived macrophages and dendritic cells. For each cell type, Y-axis values were calculated as percentage of a fold difference of Myd88 mRNA expression by qRT-PCR analysis. The fold difference was calculated as the difference between the average ΔC_T of the experimental cell type and average ΔC_T of the control cells (untreated Myd88^+/−) divided by the control ΔC_T. 

(b-e) Graphs of the relative mRNA expression levels of (b, d) TNF- α and (c, e) Ptgs2 in bone marrow derived macrophages and dendritic cells. Cells were either (b, c) untreated or (d, e) treated with 10 ng of LPS for 1 hr. For each cell type, Y-axis values were a fold difference between the average ΔC_T of the experimental cell type and average ΔC_T of the control cells (untreated Myd88^+/−) divided by the control ΔC_T. Mean values ± SEM were plotted for each group (N=9-12 samples/group performed in 2-3 separate experiments). Asterisks indicate a statistically significant difference between two indicated groups (*P<0.05, **P<0.01, ***P<0.001) as determined by a one-way ANOVA and Tukey’s post-test.
Figure 4. *Mlcr* mice maintained crypt morphology during DSS treatment
H&E stained sections of descending colons from (a, d) *Myd88*+/−, (b, e) *Myd88*−/−, and (c, f) *Mlcr* mice. (a-c) Water treated controls and (d-f) mice treated with 2.5% DSS in drinking water for 7 days. Crypts from DSS-treated *Myd88*−/− mice were atrophic (arrows). Descending colonic crypts from DSS-treated *Myd88*+/− and *Mlcr* mice were similar in morphology to corresponding untreated mice. Bar= 100 μm.
Figure 5. Mler mice maintained epithelial proliferation during DSS treatment
Images of descending colonic crypts from (a, d) Myd88+/−, (b, e) Myd88−/−, and (c, f) Mler mice. Images were from mice that were either (a-c) water treated or (d-f) DSS-treated. Each figure includes sections that were stained with either (left panel) H&E or (right panel) goat-anti-BrdU antisera, Alex-Fluor 594-labeled donkey anti-goat IgG (red) and bis-benzamide (blue). The crypt epithelial-mesenchyme junctions (white dotted lines) and the epithelial crypt-surface junctions (white dashed lines) are indicated. Bar=15 μm. Quantification of epithelial proliferation as determined by (g) S-phase (BrdU incorporation) and (h) M-phase analysis. Quantification of (i) crypt cell census and (j) epithelial apoptosis (apoptotic body counts on H+E). Mean values ± SEM were plotted for each group (N=8 mice/group analyzed in a total of three separate experiments; 100 well oriented crypt units analyzed/mouse). Asterisks indicate a statistically significant difference between DSS-treated and corresponding untreated controls (*P<0.05, **P<0.01, ***P<0.001) by one way ANOVA and Tukey’s post-test.
Figure 6. Mlcr macrophages express elevated CD86 during DSS treatment

(a, b) Image of the basal half of a descending colonic crypt and associated mesenchyme from a Myd88<sup>+/−</sup> mouse. Sections were stained with rat-anti-mouse CD86 antisera directly conjugated PerCP (red), rat anti-mouse F4/80 antisera directly conjugated to Alex-Fluor 488 (green) and bis-benzamide (blue). The epithelial-mesenchyme junction is delineated by a white dotted line. Inset in (b) shows CD86 positive aggregates that either co-localized with F4/80 (yellow, arrows) or did not co-localize with F4/80 (red, double head arrow). Bar=15 μm.

(c, d) Graph of (c) the number of CD86 aggregates that co-localize with F4/80 per crypt associated mesenchymal area and (d) the percentage of CD86 aggregates that co-localized with F4/80. Mean values ± SEM were plotted for each group (N=4 mice/group analyzed from 2 separate experiments; N=100 crypt associated mesenchyme units were evaluated per mouse). Asterisks indicate statistically significant differences between indicated groups (*P<0.05, **P<0.01, ***P<0.001) as determined by ANOVA and Tukey’s post-test.
Figure 7. Colonic fibroblasts express Ptgs2 in Mlcr mice
(a-f) Images of descending colonic crypts and surrounding mesenchyme from (a, d) Myd88<sup>+/−</sup>, (b, e) Myd88<sup>−/−</sup> and (c, f) Mlcr mice. Images from mice that were either (a-c) water treated or (d-f) DSS-treated mice. Sections were stained with mouse-anti-Ptgs2 antisera labeled with Alex-Fluor 594 (red), rat anti-mouse F4/80 antisera directly conjugated to Alexa-Fluor 488 (green), rat anti-mouse CD11c antisera directly conjugated to Alexa-Fluor 647 (pink) and bis-benzamide (blue). The crypt epithelialmesenchyme junctions (white dotted lines) are indicated. The arrows indicate mesenchymal cells that were Ptgs2 positive. Bars=15 μm. (g) Graph of the number of Ptgs2-positive cells (fibroblasts) per 100 crypt-mesenchyme units for the indicated genotypes and treatments (N=6 mice/group analyzed from two separate experiments; N=100 crypt-mesenchyme units evaluated/mouse). (h) Graph of the relative mRNA expression levels of Ptgs2 in isolated colonic fibroblasts and myeloid cells. Y-axis values were a fold-difference between the average ΔC<sub>T</sub> of the experimental cell type and average ΔC<sub>T</sub> of the control cells (Myd88<sup>+/−</sup> myeloid cells) divided by the control ΔC<sub>T</sub>. Mean values ± SEM were plotted for each group (N=4 mice/group analyzed from 2 separate experiments). Asterisks indicate a statistically significant difference between indicated groups (**P<0.01, ***P<0.001) as determined by ANOVA and Tukey’s post-test.
Figure 8. Ptgs2-expressing stromal cells are preferentially distributed in the crypt base associated mesenchyme of Mlcr mice
(a) Map of three mesenchymal zones associated with distinct populations of epithelial cells (Panel A; Upper=red, surface, middle=blue, post-mitotic crypt, lower=green, proliferative crypt base). Bar=5 μm. (b) Graph of the fractional representation of Ptgs2-expressing stromal cells located in each mesenchymal zone for each genotype calculated with and without DSS treatment (N=6 mice/group analyzed from two separate experiments; N=100 crypt-mesenchyme units analyzed/mouse). Asterisks indicate a statistically significant difference in fractional representation in the lower mesenchyme when comparing treated to untreated for a given genotype (*P<0.05, Student’s t test).
Figure 9. Untreated Mlcr mice contain mildly activated myeloid cells
Graph of the relative mRNA expression levels of multiple markers of myeloid cell activation. For each gene, Y-axis values were a fold-difference between the average $\Delta C_T$ of the experimental cell type and average $\Delta C_T$ of the control cells (Myd88$^{+/−}$ myeloid cells) divided by the control $\Delta C_T$. Mean values ± SEM were plotted for each group (N=4 mice/group analyzed from 2 separate experiments). Asterisks indicate a statistically significant difference between indicated groups (**P<0.01, ***P<0.001) as determined by ANOVA and Tukey’s post-test.
Table I

*Mlcr* mice exhibited improved survival as compared to *Myd88*<sup>−/−</sup> littermates

Survival table of Actual vs. Expected birthrates for the two breeding schemes used to generate littermate controls. Asterisks indicate a statistically significant difference between groups (*P*<0.05, Chi-squared test).

<table>
<thead>
<tr>
<th>Breeding Scheme</th>
<th>Parents</th>
<th>Myd88&lt;sup&gt;−/−&lt;/sup&gt;</th>
<th>LysM&lt;sup&gt;Cre+&lt;/sup&gt;</th>
<th>Rosa26R&lt;sup&gt;Myd88+&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[Image]</td>
<td>+/−</td>
<td>+/−</td>
<td>+/−</td>
</tr>
<tr>
<td></td>
<td>[Image]</td>
<td>−/−</td>
<td>+/−</td>
<td>+/−</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[Image]</td>
<td>−/−</td>
<td>+/−</td>
<td>+/−</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Breeding Scheme 1</th>
<th>Myd88&lt;sup&gt;−/−&lt;/sup&gt;</th>
<th><em>Mlcr</em></th>
<th>Myd88&lt;sup&gt;+/−&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Mice</td>
<td>14</td>
<td>27</td>
<td>39</td>
</tr>
<tr>
<td>Actual</td>
<td>17%</td>
<td>34%</td>
<td>49%</td>
</tr>
<tr>
<td>Expected (Mendelian)</td>
<td>22%</td>
<td>28%</td>
<td>50%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Breeding Scheme 2</th>
<th>Myd88&lt;sup&gt;−/−&lt;/sup&gt;</th>
<th><em>Mlcr</em></th>
<th>Myd88&lt;sup&gt;+/−&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Mice</td>
<td>21</td>
<td>59</td>
<td>N/A</td>
</tr>
<tr>
<td>Actual</td>
<td>26%**</td>
<td>74%**</td>
<td></td>
</tr>
<tr>
<td>Expected (Mendelian)</td>
<td>44%</td>
<td>56%</td>
<td></td>
</tr>
</tbody>
</table>
### Table II

**Interpretation of Mlcr genotyping**

PCR product sizes that correspond to each genotype are indicated.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>746 Band</th>
<th>538 band</th>
<th>342 Band</th>
</tr>
</thead>
<tbody>
<tr>
<td>MydRosa+ Myd88&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>MydRosa− Myd88&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>MydRosa+&lt;sup&gt;+&lt;/sup&gt; Myd88&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>MydRosa−&lt;sup&gt;+&lt;/sup&gt; Myd88&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>MydRosa+ Myd88&lt;sup&gt;+/+&lt;/sup&gt;</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>MydRosa− Myd88&lt;sup&gt;+/+&lt;/sup&gt;</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>